Q3 Results 2008

30 October 2008 Earnings call



Profit & Loss: Key Figures (in million Euro)

	Q3 '07	Q3 '08	% change (excl. curr.)	9M '07	9M '08	% change (excl. curr.)
Sales	788	741	-6.0% (-1.7%)	2,419	2,271	-6.1% (-1.3%)
Gross profit	261	223	-14.6%	867	733	-15.5%
as a % of sales	33.1%	30.1%		35.8%	32.3%	
R&D	-47	-41	-12.8%	-141	-135	-4.3%
SG&A*	-181	-154	-14.9%	-569	-491	-13.7%
as a % of sales	23.0%	20.8%		23.5%	21.6%	
Other operating items*	-8	-1		-20	-1	
Recurring EBITDA*	65	55	-15.4%	248	193	-22.2%
as a % of sales	8.3%	7.4%		10.3%	8.5%	
Recurring EBIT*	25	27	8.0%	138	106	-23.2%
as a % of sales	3.2%	3.6%		5.7%	4.7%	

* Before restructuring charges and non-recurring items.

Sales decline excluding currency effects in line with previous quarters


Effects of economic slowdown become more visible

Gross profit impacted by higher raw material costs (19 million Euro) and one-off elements

Continued strong SG&A reduction in all business groups




Net Financial Debt (in million Euro)




Target to decrease net financial debt by end of year to level below 650 million Euro




Working Capital: Key Figures (in million Euro/days)





Trade Payables

1000





Main Drivers behind Key Figures

- Sales at 741 million Euro decrease of 1.7% (excluding currency effects) due to strong Euro and economic slowdown
- Margins impacted by 19 million Euro higher raw material costs (mainly silver) and by one-off elements
- Decrease of SG&A costs with 27 million Euro (of which 5 million currency impact) due to continued efforts to improve efficiency
- Recurring EBIT at 27 million Euro Net result at -13 million Euro
- Net financial debt at 723 million Euro versus 852 million Euro in the third quarter of 2007



Profit & Loss: Key Figures (in million Euro)

	Q3 '07	Q3 '08	% change	9M '07	9M '08	% change
Recurring EBIT*	25	27	+8.0%	138	106	-23.2%
Restructuring and non-recurring	-18	-8		-39	-24	
Operating result	7	19	+171.4%	99	82	-17.2%
Non-operating result	-26	-24		-45	-66	
Profit before taxes	-19	-5		54	16	
Taxes and minority interest	5	-8		15	-16	
Net result	-14	-13		69	0	

* Before restructuring charges and non-recurring items.



Agfa Graphics



Graphics: Key Figures (in million Euro)

	Q3 '07	Q3 '08	% change (excl. curr.)	9M '07	9M '08	% change (excl. curr.)
Sales	400	377	-5.8% (-1.2%)	1,201	1,140	-5.1% (-0.1%)
Gross profit	122	107	-12.3%	381	348	-8.7%
as a % of sales	30.5%	28.4%		31.7%	30.5%	
R&D	-20	-14	-30.0%	-60	-49	-18.3%
SG&A*	-86	-76	-11.6%	-266	-243	-8.6%
as a % of sales	21.5%	20.2%		22.2%	21.3%	
Other operating items*	-3	-2		-9	-10	
Recurring EBITDA*	29.4	28.6	-2.7%	94.1	85.5	-9.1%
as a % of sales	7.4%	7.6%		7.8%	7.5%	
Recurring EBIT*	13.4	15.6	+16.4%	46.1	46.5	+0.9%
as a % of sales	3.4%	4.1%		3.8%	4.1%	


* Before restructuring charges and non-recurring items.

Minor sales decrease excluding currency effects due to price pressure and economic slowdown

8 million Euro impact of raw material costs offset by continued focus on cost savings



Graphics: YTD Sales per Business Segment





Graphics: Main Drivers behind Key Figures

- Minor sales decrease excluding currency effects due to economic slowdown and related pricing pressure
 - Continued growth in digital plates more than offset decline of analog business
 - First revenues of finalized first generation inkjet at drupa
 - Adverse one-off effects
- Gross profit impacted by 8 million Euro higher raw material costs
- Further accelerated reduction in SG&A costs
- Decrease of inkjet losses in line with plan



Agfa HealthCare



HealthCare: Key Figures (in million Euro)

	Q3 '07	Q3 '08	% change (excl. curr.)	9M '07	9M '08	% change (excl. curr.)
Sales	319	291	-8.8% (-4.2%)	1,018	898	-11.8% (-6.8%)
Gross profit	124	102	-17.7%	435	342	-21.4%
as a % of sales	38.9%	35.1%		42.7%	38.1%	
R&D	-25	-25	0.0%	-77	-80	+3.9%
SG&A*	-88	-72	-18.2%	-280	-226	-19.3%
as a % of sales	27.6%	24.7%		27.5%	25.3%	
Other operating items*	-4	2		-11	8	
Recurring EBITDA*	29.4	21.0	-28.6%	124.7	87.7	-29.7%
as a % of sales	9.2%	7.2%		12.3%	9.8%	
Recurring EBIT*	6.4	7.0	+9.4%	66.7	43.7	-34.5%
as a % of sales	2.0%	2.4%		6.6%	4.9%	

* Before restructuring charges and non-recurring items.


Sales excluding currency effects slightly better than trend

Strong Euro still impacts competitive position

Significant SG&A reduction



HealthCare: YTD Sales per Business Segment



* Includes Radiology and Cardiology IT



HealthCare: Main Drivers behind Key Figures

- Weakness in US and Western European markets
- Sales decrease excluding currency effects mainly driven by impact of strong Euro on competitive position
 - Market driven decline of classical film
 - Good performance of Hardcopy Dry
 - Decrease in Imaging IT due to impact of NHS contract in Q3'07
 - Recovery of HIS/CIS revenues versus Q3'07
- Good momentum in emerging countries
- Continued significant reduction of SG&A costs (-18.2%)
- EBIT affected by silver costs (9 million Euro), sales decline and unfavorable mix effects



Agfa Materials



Materials: Pro Forma Sales

(in million Euro)	Q3 '07	Q3 '08	9M '07	9M '08
Internal sales*	116	95	354	315
Specialty Products	69	73	200	233
TOTAL	185	168	554	548

* Sales to Agfa Graphics and Agfa HealthCare



Specialty Products: Key Figures (in million Euro)

	Q3 '07	Q3 '08	% change (excl. curr.)	9M '07	9M '08	% change (excl. curr.)
Sales	69	73	+5.8% (+7.2%)	200	233	+16.5% (+18.3%)
Gross profit	16	14	-12.5%	53	43	-18.9%
as a % of sales	23.2%	19.2%		26.5%	18.5%	
R&D	-2	-1	-50.0%	-4	-6	+50.0%
SG&A*	-7	-7	0.0%	-23	-21	-8.7%
as a % of sales	10.1%	9.6%		11.5%	9.0%	
Other operating items*	0	0		2	1	
Recurring EBITDA*	8.3	6.2	-25.3%	32.0	20.9	-34.7%
as a % of sales	12.0%	8.5%		16.0%	9.0%	
Recurring EBIT*	7.3	5.2	-28.8%	28.0	16.9	-39.6%
as a % of sales	10.6%	7.1%		14.0%	7.3%	

* Before restructuring charges and non-recurring items.

Sales increase driven by large volume contracts

Profitability negatively impacted by mix effects, silver price, inventory writedowns and fierce competition in traditional markets



Specialty Products: Main Drivers behind Key Figures

- Sales increase of 7.2% excluding currency effects
 - Mainly driven by large volume contracts in Film Manufacturing Services
 - Market-driven declining trend in some traditional products
- Impact of raw materials (3 million Euro)
- On track with efforts to reduce operational costs
- Profitability negatively impacted by mix effect, silver price and inventory write-downs



Outlook

- Agfa Group
 - Further effects of global economic slowdown
 - First positive effects of exchange rates and raw material prices will show as from the beginning of 2009
 - Continued focus on reduction of the operational costs: 120 million Euro by end of 2010
 - In view of the economic slowdown, additional cost reduction initiatives are being taken to protect the gross margin
- Graphics
 - Effects of economic slowdown increasingly visible
 - Further decline in analog prepress and growth in digital prepress
 - Growth expected in inkjet in 2009, although growth rate could be affected by economic slowdown
- HealthCare
 - Effects of economic slowdown increasingly visible, mainly in HealthCare IT
 - Present trend in Imaging sales is expected to continue, but results will be protected by additional savings
 - IT revenues will benefit from the APHP deal in 2009
- Specialty Products
 - Strengthening its position as leading supplier in traditional film markets
 - Focus on new growth markets such as synthetic paper SYNAPS and Zirfon® Perl membranes



Questions & Answers

